Trending...
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
WEST CHESTER, Pa.--(BUSINESS WIRE)--Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent director of the Company's Board of Directors and as Chair of the Audit Committee.
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
- Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
- Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
- Timbrana Addresses the Missing Follow-Through in Commercial Construction Projects
- AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
- UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
0 Comments
Latest on The PennZone
- AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
- DayPass llega a ChatGPT y Claude
- DayPass launches in ChatGPT and Claude
- Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
- Victor Archibong Expands ItsArchiDuh Creator Brand
- Talented Learning Unveils 2026 LMS Award Winners
- Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
- Revinate launches hospitality's first data activation platform
- HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
- BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
- Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
- Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1